Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307777231> ?p ?o ?g. }
- W4307777231 endingPage "253" @default.
- W4307777231 startingPage "242" @default.
- W4307777231 abstract "VERVE-101 is an investigational in vivo CRISPR base-editing medicine designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic protein production, and thereby durably lower low-density lipoprotein cholesterol. We test the efficacy, durability, tolerability, and potential for germline editing of VERVE-101 in studies of nonhuman primates and a murine F1 progeny study.Cynomolgus monkeys were given a single intravenous infusion of a vehicle control (n=10) or VERVE-101 at a dose of 0.75 mg/kg (n=4) or 1.5 mg/kg (n=22) with subsequent follow-up up to 476 days. Two studies assessed the potential for germline editing, including sequencing sperm samples from sexually mature male nonhuman primates treated with VERVE-101 and genotyping offspring from female mice treated with the murine surrogate of VERVE-101 (VERVE-101mu).Liver biopsies 14 days after dosing noted mean PCSK9 editing of 46% and 70% in monkeys treated with VERVE-101 at 0.75 and 1.5 mg/kg, respectively. This translated into mean reductions in blood PCSK9 (proprotein convertase subtilisin/kexin type 9) of 67% and 83% and reductions of low-density lipoprotein cholesterol of 49% and 69% at the 0.75 and 1.5 mg/kg doses, respectively, assessed as time-weighted average change from baseline between day 28 and up to 476 days after dosing. Liver safety monitoring noted a transient rise in alanine aminotransferase and aspartate aminotransferase concentrations after infusion that fully resolved by day 14 with no accompanying change in total bilirubin. In a subset of monkeys necropsied 1 year after dosing, no findings related to VERVE-101 were identified on macroscopic and histopathologic assessment of the liver and other organs. In the study to assess potential germline editing of male nonhuman primates, sperm samples collected after VERVE-101 dosing showed no evidence of PCSK9 editing. Among 436 offspring of female mice treated with a saturating dose of VERVE-101mu, the PCSK9 edit was transmitted in 0 of 436 animals.VERVE-101 was well tolerated in nonhuman primates and led to 83% lower blood PCSK9 protein and 69% lower low-density lipoprotein cholesterol with durable effects up to 476 days after dosing. These results have supported the initiation of a first-in-human clinical trial in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease." @default.
- W4307777231 created "2022-11-05" @default.
- W4307777231 creator A5014745056 @default.
- W4307777231 creator A5023596027 @default.
- W4307777231 creator A5030786234 @default.
- W4307777231 creator A5037482943 @default.
- W4307777231 creator A5038767378 @default.
- W4307777231 creator A5040642674 @default.
- W4307777231 creator A5052804569 @default.
- W4307777231 creator A5058259636 @default.
- W4307777231 creator A5090160192 @default.
- W4307777231 date "2023-01-17" @default.
- W4307777231 modified "2023-10-16" @default.
- W4307777231 title "Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting <i>PCSK9</i> in Nonhuman Primate and Mouse Models" @default.
- W4307777231 cites W1992365936 @default.
- W4307777231 cites W2056411372 @default.
- W4307777231 cites W2066622255 @default.
- W4307777231 cites W2067539811 @default.
- W4307777231 cites W2080718344 @default.
- W4307777231 cites W2110083155 @default.
- W4307777231 cites W2122771422 @default.
- W4307777231 cites W2122833169 @default.
- W4307777231 cites W2129809363 @default.
- W4307777231 cites W2135290312 @default.
- W4307777231 cites W2141627409 @default.
- W4307777231 cites W2163488353 @default.
- W4307777231 cites W2253584908 @default.
- W4307777231 cites W2465758073 @default.
- W4307777231 cites W2555483953 @default.
- W4307777231 cites W2582372330 @default.
- W4307777231 cites W2595169180 @default.
- W4307777231 cites W2596179513 @default.
- W4307777231 cites W2609543937 @default.
- W4307777231 cites W2766569988 @default.
- W4307777231 cites W2811289319 @default.
- W4307777231 cites W2867029183 @default.
- W4307777231 cites W2899997727 @default.
- W4307777231 cites W2914546434 @default.
- W4307777231 cites W2969949762 @default.
- W4307777231 cites W3011005820 @default.
- W4307777231 cites W3012265841 @default.
- W4307777231 cites W3015621743 @default.
- W4307777231 cites W3048426063 @default.
- W4307777231 cites W3048679999 @default.
- W4307777231 cites W3102991281 @default.
- W4307777231 cites W3120916025 @default.
- W4307777231 cites W3130321596 @default.
- W4307777231 cites W3155280715 @default.
- W4307777231 cites W3159373679 @default.
- W4307777231 cites W3161425918 @default.
- W4307777231 cites W3163681195 @default.
- W4307777231 cites W3170272938 @default.
- W4307777231 cites W3177445623 @default.
- W4307777231 cites W3183857127 @default.
- W4307777231 cites W3188073678 @default.
- W4307777231 cites W3198898259 @default.
- W4307777231 cites W4205428823 @default.
- W4307777231 cites W4211152466 @default.
- W4307777231 cites W4220771406 @default.
- W4307777231 cites W4236190976 @default.
- W4307777231 cites W4283732121 @default.
- W4307777231 doi "https://doi.org/10.1161/circulationaha.122.062132" @default.
- W4307777231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36314243" @default.
- W4307777231 hasPublicationYear "2023" @default.
- W4307777231 type Work @default.
- W4307777231 citedByCount "30" @default.
- W4307777231 countsByYear W43077772312022 @default.
- W4307777231 countsByYear W43077772312023 @default.
- W4307777231 crossrefType "journal-article" @default.
- W4307777231 hasAuthorship W4307777231A5014745056 @default.
- W4307777231 hasAuthorship W4307777231A5023596027 @default.
- W4307777231 hasAuthorship W4307777231A5030786234 @default.
- W4307777231 hasAuthorship W4307777231A5037482943 @default.
- W4307777231 hasAuthorship W4307777231A5038767378 @default.
- W4307777231 hasAuthorship W4307777231A5040642674 @default.
- W4307777231 hasAuthorship W4307777231A5052804569 @default.
- W4307777231 hasAuthorship W4307777231A5058259636 @default.
- W4307777231 hasAuthorship W4307777231A5090160192 @default.
- W4307777231 hasBestOaLocation W43077772311 @default.
- W4307777231 hasConcept C126322002 @default.
- W4307777231 hasConcept C134018914 @default.
- W4307777231 hasConcept C16685009 @default.
- W4307777231 hasConcept C197934379 @default.
- W4307777231 hasConcept C2777288759 @default.
- W4307777231 hasConcept C2778163477 @default.
- W4307777231 hasConcept C2778375690 @default.
- W4307777231 hasConcept C2779594886 @default.
- W4307777231 hasConcept C2780072125 @default.
- W4307777231 hasConcept C2780948078 @default.
- W4307777231 hasConcept C43554185 @default.
- W4307777231 hasConcept C71924100 @default.
- W4307777231 hasConcept C98274493 @default.
- W4307777231 hasConceptScore W4307777231C126322002 @default.
- W4307777231 hasConceptScore W4307777231C134018914 @default.
- W4307777231 hasConceptScore W4307777231C16685009 @default.
- W4307777231 hasConceptScore W4307777231C197934379 @default.
- W4307777231 hasConceptScore W4307777231C2777288759 @default.
- W4307777231 hasConceptScore W4307777231C2778163477 @default.